Beta cell specific ZnT8 gene deficiency and resulting loss in zinc content significantly improve insulin secretion
Molecular and Cellular Endocrinology · 2024
DOI: 10.1016/j.mce.2024.112376 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular and Cellular Endocrinology, 2024. Verfasst von Anthony Piro und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Zinc Transporter 8, Zinc, Insulin-Secreting Cells, Insulin Secretion. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Juvenile Diabetes Research Foundation Canada, American University in Cairo, Hospital for Sick Children.
Abstract (Originalsprache)
Zinc transporter 8 (ZnT8) is highly expressed in pancreatic beta cells, localizes to insulin secretory granules (ISG), and regulates zinc content. ZnT8 gene polymorphisms have revealed a relationship between ZnT8 activity and type 2 diabetes (T2D) risk, however, the role of beta-cell ZnT8 is not well understood. A beta cell specific ZnT8 knockout (ZnT8 BKO) mouse model was investigated. ZnT8 BKO islets showed significantly reduced ZnT8 gene expression and reduced zinc content. Compared to controls, ZnT8 BKO mice displayed significantly elevated plasma insulin levels and improved glucose tolerance following acute insulin resistance induced via S961. Glucose stimulated insulin secretion from isolated ZnT8 BKO pancreatic islets revealed enhanced insulin secretion capacity. The difference in insulin secretion between ZnT8 BKO and control islets was negated upon zinc supplementation, and the inhibitory effect of zinc on insulin secretion was confirmed in human islets. These results indicate that the loss of ZnT8 activity and accompanying reduced cellular zinc are associated with increased insulin secretion capacity. The reduction in secreted insulin content upon zinc supplementation in ZnT8 BKO islets suggests that ISG-released zinc normally tempers insulin secretion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Department of Physiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Endocrinology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
- Advanced Diagnostics, Toronto General Hospital Research Institute, Toronto, ON M5G 1L7, Canada; Institute of Biomedical Engineering, University of Toronto, Toronto, ON M5S 3G9, Canada.
- Department of Physiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: michael.wheeler@utoronto.ca.
Förderung
- Juvenile Diabetes Research Foundation Canada
- American University in Cairo
- Hospital for Sick Children
- Canadian Institutes of Health Research
Zitieren
APA
Piro, A., Luo, Y., Zhang, Z., Ye, W., Kang, F., Xie, L., Wang, Y., Dai, F. F., Gaisano, H. Y., Rocheleau, J. V., Prentice, K. J., & Wheeler, M. B. (2024). Beta cell specific ZnT8 gene deficiency and resulting loss in zinc content significantly improve insulin secretion. Molecular and Cellular Endocrinology. https://doi.org/10.1016/j.mce.2024.112376
Vancouver
Piro A, Luo Y, Zhang Z, Ye W, Kang F, Xie L, et al. Beta cell specific ZnT8 gene deficiency and resulting loss in zinc content significantly improve insulin secretion. Molecular and Cellular Endocrinology. 2024. doi:10.1016/j.mce.2024.112376
BibTeX
@article{Piro2024,
author = {Piro, Anthony and Luo, Yihan and Zhang, Ziyi and Ye, Wenyue and Kang, Fei and Xie, Li and Wang, Yufeng and Dai, Feihan F and Gaisano, Herbert Y and Rocheleau, Jonathan V and Prentice, Kacey J and Wheeler, Michael B},
title = {Beta cell specific ZnT8 gene deficiency and resulting loss in zinc content significantly improve insulin secretion},
journal = {Molecular and Cellular Endocrinology},
year = {2024},
doi = {10.1016/j.mce.2024.112376}
}
EUVIMED